10-QPeriod: Q1 FY2012

MCKESSON CORP Quarterly Report for Q1 Ended Jun 30, 2011

Filed July 28, 2011For Securities:MCK

Summary

McKesson Corporation's 10-Q filing for the quarter ended June 29, 2011, reveals a company operating with strong revenue growth, a common theme in the pharmaceutical distribution sector. While specific figures are not detailed in the provided excerpt, the inclusion of condensed consolidated statements of operations, balance sheets, and cash flows indicates a thorough review of the company's financial health and performance. Investors should pay close attention to the Management's Discussion and Analysis (MD&A) section, which would typically elaborate on the drivers behind revenue changes, profitability, and any significant operational developments impacting the quarter. The filing also highlights crucial elements like Legal Proceedings and Risk Factors, which are vital for understanding potential headwinds or uncertainties facing McKesson. For investors, understanding the company's liquidity, debt levels, and overall financial stability, as presented in the balance sheets and cash flow statements, is paramount. The overall tone of a 10-Q filing typically focuses on providing transparency regarding the company's current financial standing and outlook, allowing investors to make informed decisions.

Financial Highlights

52 data points
Beta

Revenue

$29.98B

5.0% Gross Margin

Net Income

$286.00M

1.0% Net Margin

EPS (Diluted)

$1.13

Total Assets

$31.02B

Cash & Equivalents

$3.12B

Free Cash Flow

$268.00M

Financial Statements
Beta
Revenue$29.98B
Cost of Revenue$28.47B
Gross Profit$1.51B
Operating Expenses$1.04B
Operating Income$472.00M
Net Income$286.00M
EPS (Basic)$1.15
EPS (Diluted)$1.13
Shares Outstanding (Basic)249.00M
Shares Outstanding (Diluted)254.00M

Key Highlights

  • 1The report covers the fiscal quarter ending June 29, 2011, providing a snapshot of McKesson's recent operational and financial performance.
  • 2Key financial statements, including Statements of Operations, Balance Sheets, and Cash Flows, are presented for investor review.
  • 3Management's Discussion and Analysis (MD&A) is expected to provide detailed insights into the company's financial condition and results of operations.
  • 4The filing includes sections on Legal Proceedings and Risk Factors, which are critical for assessing potential liabilities and business challenges.
  • 5The report structure suggests a comprehensive review of the company's financial health, operational efficiency, and forward-looking risks.
  • 6Investors can gauge McKesson's revenue generation, profitability trends, and cash management strategies through the provided financial statements.

Frequently Asked Questions

The provided excerpt does not detail specific revenue drivers. However, typically for McKesson, revenue growth is influenced by factors such as pharmaceutical price inflation, volume growth from sales to retail pharmacies, hospital systems, and government agencies, as well as acquisitions and the performance of its specialty pharmaceutical businesses.

The filing indicates a 'Legal Proceedings' section. Investors should review this section in the full 10-Q report to understand any ongoing litigation, investigations, or settlements that could result in financial penalties or operational disruptions.

The 'Risk Factors' section of the 10-Q is designed to address this. Potential risks for a company like McKesson could include regulatory changes, competition, integration of acquisitions, supply chain disruptions, and pricing pressures from payers and manufacturers.

The 'Condensed Consolidated Statements of Cash Flows' and 'Condensed Consolidated Balance Sheets' provide insights into McKesson's cash generation, operating activities, investing activities, and financing activities, as well as its short-term and long-term assets and liabilities. Investors should examine these statements to assess liquidity and debt management.